Skip to main content
Premium Trial:

Request an Annual Quote

BD Biosciences Clontech s BD Knockout Inducible RNAi System and Living Colors DsRed-Monomer Fluorescent Protein and Serologicals Upstate Group s PathwayProfiler


BD Biosciences Clontech has recently introduced the BD Knockout inducible RNAi system.

According to the company, the system features inducible retroviral shRNA expression vectors, which are provided linearized and ready for ligation with a dsDNA oligonucleotide encoding an shRNA. It uses a modified tetracycline-controlled gene-expression system in which expression of an shRNA is induced when either tetracycline or doxycycline is added to the culture medium of an appropriately engineered cell.

Additional details about the inducible RNAi system can be found at

BD Biosciences Clontech has also introduced its Living Colors DsRed-Monomer Fluorescent Protein, a newly engineered mutant of the company’s fluorescent protein from Discosoma reef coral.

DsRed-Monomer is ideal for applications in flow cytometry and fluorescence microscopy, BD said. It is also extremely stable, according to the company, allowing researchers to monitor fluorescence as much as 12 hours following transfection.

Upstate Group, a division of Serologicals, has announced the introduction of PathwayProfiler, a service that measures cell-based signaling cascades and provides drug development companies with information about compound efficacy.


The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more